KR101380190B1 - 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체 - Google Patents

벤조 〔ｄ〕〔１,３〕―디옥솔 유도체 Download PDF

Info

Publication number
KR101380190B1
KR101380190B1 KR1020087004867A KR20087004867A KR101380190B1 KR 101380190 B1 KR101380190 B1 KR 101380190B1 KR 1020087004867 A KR1020087004867 A KR 1020087004867A KR 20087004867 A KR20087004867 A KR 20087004867A KR 101380190 B1 KR101380190 B1 KR 101380190B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
deuterium
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087004867A
Other languages
English (en)
Korean (ko)
Other versions
KR20080039949A (ko
Inventor
로거 텅
Original Assignee
콘서트 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘서트 파마슈티컬즈, 인크. filed Critical 콘서트 파마슈티컬즈, 인크.
Publication of KR20080039949A publication Critical patent/KR20080039949A/ko
Application granted granted Critical
Publication of KR101380190B1 publication Critical patent/KR101380190B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
KR1020087004867A 2005-07-29 2006-07-28 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체 Expired - Fee Related KR101380190B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70407305P 2005-07-29 2005-07-29
US60/704,073 2005-07-29
PCT/US2006/029599 WO2007016431A2 (en) 2005-07-29 2006-07-28 Novel benzo [d] [1,3]-dioxol derivatives

Publications (2)

Publication Number Publication Date
KR20080039949A KR20080039949A (ko) 2008-05-07
KR101380190B1 true KR101380190B1 (ko) 2014-04-11

Family

ID=37709249

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087004867A Expired - Fee Related KR101380190B1 (ko) 2005-07-29 2006-07-28 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체

Country Status (12)

Country Link
US (5) US20080287495A1 (enExample)
EP (1) EP1910322B1 (enExample)
JP (1) JP5301991B2 (enExample)
KR (1) KR101380190B1 (enExample)
CN (1) CN101273024A (enExample)
AU (1) AU2006275595B2 (enExample)
BR (1) BRPI0615973A2 (enExample)
CA (1) CA2616383C (enExample)
EA (1) EA014432B1 (enExample)
ES (1) ES2396365T3 (enExample)
WO (1) WO2007016431A2 (enExample)
ZA (1) ZA200800785B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
WO2007058998A2 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CN101460461B (zh) * 2006-04-03 2012-10-03 弗·哈夫曼-拉罗切有限公司 对映体富集的环β-芳基或杂芳基羧酸的制备方法
US20080139563A1 (en) * 2006-10-23 2008-06-12 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
EP2139877B1 (en) * 2007-03-07 2011-05-11 Concert Pharmaceuticals Inc. Deuterated piperazine derivatives as anti-anginal compounds
DK3825306T3 (da) 2007-05-01 2023-09-11 Sun Pharmaceutical Ind Inc Morphinanforbindelser
MX370608B (es) * 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
US7608737B2 (en) * 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
KR20100047190A (ko) * 2007-06-13 2010-05-07 오스펙스 파마슈티칼스, 인코포레이티드 치환 피페라진
CA2698808A1 (en) * 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
AR072511A1 (es) * 2008-07-15 2010-09-01 Theracos Inc Derivados deuterados de bencilbenceno y metodos de uso. composicion farmaceutica.
WO2010010141A1 (en) * 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Pramipexole for treating cardiomyopathy
US20100093721A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EA020117B1 (ru) * 2008-11-14 2014-08-29 Консерт Фармасьютикалс Инк. Замещенные диоксопиперидинилфталимидные производные
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US20100143505A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Indanone inhibitors of acetylcholinesterase
US20100159034A1 (en) * 2008-12-15 2010-06-24 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
CN104829531A (zh) * 2009-10-26 2015-08-12 大塚制药株式会社 苯并氮杂*化合物
WO2011159920A1 (en) * 2010-06-17 2011-12-22 Concert Pharmaceuticals, Inc. [5,6]-dihydro-2h-pyran-2-one derivatives
PE20150928A1 (es) 2011-06-20 2015-06-26 Lundbeck & Co As H 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
JP6055784B2 (ja) * 2012-01-31 2016-12-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 パロキセチン誘導体
US8586552B2 (en) 2012-02-03 2013-11-19 Selectx Pharmaceuticals, Inc. 4,6-substituted 2,5-dideoxystreptamine aminoglycoside antibiotics
EP2687854A1 (en) * 2012-07-19 2014-01-22 Chiron AS Test kit for the quantitative determination of narcotic drugs
WO2014066243A1 (en) 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
MX2015011456A (es) 2013-03-13 2016-05-31 Boston Biomedical Inc Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer.
AU2014300673B2 (en) * 2013-06-27 2017-12-14 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
ES2835874T3 (es) 2014-07-29 2021-06-23 Shenzhen Hightide Biopharmaceutical Ltd Sales de berberina, sales ursodesoxicólicas y combinaciones, procedimientos de preparación y aplicación de las mismas
US10037449B1 (en) 2015-09-29 2018-07-31 Amazon Technologies, Inc. Inventory tracking using RFID
US10089505B1 (en) 2015-09-29 2018-10-02 Amazon Technologies, Inc. Inventory tracking using RFID
ES2849560T3 (es) 2016-05-04 2021-08-19 Genoscience Pharma Sas Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
EP3456328A4 (en) 2016-05-10 2020-02-26 Shenzhen Hightide Biopharmaceutical., Ltd. Composition, and application and pharmaceutical preparation thereof
CN109328018A (zh) 2016-12-15 2019-02-12 雀巢产品技术援助有限公司 调节伴侣动物体内的磷或酶的组合物和方法
CN108864077B (zh) 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法
CN109134432B (zh) * 2017-06-15 2021-06-11 北京君科华元医药科技有限公司 氘代抗抑郁药物
US11440904B2 (en) 2017-08-28 2022-09-13 Zhihong Chen Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
CN107970243B (zh) * 2017-10-30 2020-07-28 江苏理工学院 一种去甲氯氮平的新用途
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
KR102841141B1 (ko) 2018-11-01 2025-07-31 링크 파마슈티컬스 컴퍼니 리미티드 트리사이클릭 야누스 키나제 1 억제제 및 이의 조성물 및 방법
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
WO2020146845A1 (en) 2019-01-11 2020-07-16 University Of Rochester Compositions and methods for treating prostate cancer with enzalutamide and an inhibitor of monoamin oxidase a
AU2020216345B2 (en) 2019-02-01 2025-03-20 Canwell Biotech Limited Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof
US10906923B1 (en) 2019-02-07 2021-02-02 Canwell Biotech Limited Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof
CN110283156B (zh) * 2019-07-29 2020-06-30 河北省农林科学院经济作物研究所 从刺五加中提取的新型降血脂化合物
CA3152316A1 (en) 2019-10-04 2021-04-08 Scott C. Jeffrey Camptothecin peptide conjugates
US20230340491A1 (en) 2020-04-22 2023-10-26 University Of Rochester Compositions and methods for treating metabolic and cardiovascular diseases
JP2022100060A (ja) * 2020-12-23 2022-07-05 大陽日酸株式会社 モノ重水素化ジハロゲン化メタン、重水素化シクロプロパン化合物及びそれらの製造方法
WO2022169690A1 (en) 2021-02-02 2022-08-11 Yanping Kong Composition and methods for treating cancer
US20240293405A1 (en) 2021-06-22 2024-09-05 Jean Zhao (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl-acrylamide inhibitors of egfr for use in the treatment of brain tumors
WO2025126109A1 (en) 2023-12-15 2025-06-19 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
AU1966188A (en) * 1987-08-07 1989-03-09 Mallinckrodt, Inc. Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
IL133366A (en) * 1997-06-10 2005-11-20 Synthon Bv 4-Phenylpiperidine compounds, process for their preparation and uses thereof
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
BRPI0617987A2 (pt) 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
WO2007058998A2 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CA2698808A1 (en) * 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
H. J. Leis et al. Journal of Mass Spectrometry. Volume 36, pp. 923-928 (2001) *
H. J. Leis et al. Journal of Mass Spectrometry. Volume 36, pp. 923-928 (2001)*
K.L. Dechant et al. Drugs. Volume 41, Issue 2, pp. 225-253 (1991) *
R.E. Haddock et al. Acta Psychiatrica Scandinavica. Volume 80, Issue S350, pp. 24-26 (1989) *

Also Published As

Publication number Publication date
EP1910322A4 (en) 2010-09-22
US20070191432A1 (en) 2007-08-16
BRPI0615973A2 (pt) 2011-05-31
JP2009502963A (ja) 2009-01-29
US20140018390A1 (en) 2014-01-16
US8450492B2 (en) 2013-05-28
EP1910322A2 (en) 2008-04-16
EP1910322B1 (en) 2012-09-05
CA2616383C (en) 2015-06-09
KR20080039949A (ko) 2008-05-07
US7678914B2 (en) 2010-03-16
ZA200800785B (en) 2009-01-28
WO2007016431A3 (en) 2007-07-12
CN101273024A (zh) 2008-09-24
US20100222589A1 (en) 2010-09-02
ES2396365T3 (es) 2013-02-21
AU2006275595A1 (en) 2007-02-08
AU2006275595B2 (en) 2012-08-16
JP5301991B2 (ja) 2013-09-25
WO2007016431A2 (en) 2007-02-08
CA2616383A1 (en) 2007-02-08
US20080287495A1 (en) 2008-11-20
US20150196544A1 (en) 2015-07-16
EA200800490A1 (ru) 2008-08-29
HK1117532A1 (en) 2009-01-16
EA014432B1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
KR101380190B1 (ko) 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
US20080033011A1 (en) Novel benzo[d][1,3]-dioxol derivatives
US7863274B2 (en) Deuterium enriched analogues of tadalafil as PDE5 inhibitors
KR20080047375A (ko) 약제 화합물
JP5647519B2 (ja) 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
JP5240871B2 (ja) テトラヒドロピラノクロメンガンマセレクターゼ阻害剤
EP2032561A2 (fr) Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
CN1073996C (zh) 二氢－2,3－苯并二氮杂䓬衍生物的物理形态，制备方法和用途
HK1117532B (en) Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors
CN1073995C (zh) 二氢－2,3－苯并二氮杂䓬衍生物的物理形态，制备方法和用途
KR20120051716A (ko) 벤질피페리딘 화합물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170327

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170327

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000